Sugi Predict

Sugi Predict / Compounds / SCHEMBL1815044

SCHEMBL1815044

SCHEMBL1815044

CC(C)(C)OC(=O)NC1CCN(c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.61
▸ ALDH1A1 P00352 7/20 0.61
▸ LMNA P02545 2/20 0.61
▸ DRD2 P14416 1/20 0.53
▸ HTT P42858 2/20 0.51
▸ ALOX12 P18054 1/20 0.51
▸ POLB P06746 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ CKS1B P61024 1/20 0.47
▸ SKP1 P63208 1/20 0.47
▸ SKP2 Q13309 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ SIRT6 Q8N6T7 1/20 0.47
▸ MAPK1 P28482 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3702193 0.93 MAPT (0.56) MAPTALDH1A1LMNADRD2HTT
SCHEMBL30981132 0.90 MAPT (0.56) MAPTALDH1A1LMNADRD2HTT
SCHEMBL30817389 0.89 MEN1 (0.60) MAPTALDH1A1LMNADRD2HTT
SCHEMBL27624491 0.88 MAPT (0.57) MAPTALDH1A1LMNADRD2HTT
SCHEMBL30981445 0.87 DRD2 (0.58) MAPTALDH1A1LMNADRD2HTT
SCHEMBL3256239 0.86 DRD2 (0.52) MAPTALDH1A1LMNADRD2CKS1B
SCHEMBL21553430 0.86 MAPT (0.54) MAPTALDH1A1LMNADRD2HTT
SCHEMBL21553456 0.86 MAPT (0.54) MAPTALDH1A1LMNADRD2HTT
SCHEMBL16580963 0.86 MAPT (0.54) MAPTALDH1A1LMNADRD2HTT
SCHEMBL29399554 0.85 MAPT (0.56) MAPTALDH1A1LMNADRD2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 — — US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
CN-115443269-A Substituted pyrimidines and methods of use 施万生物制药研发IP有限责任公司 2022-12-06 — — CN disclosed
CN-111372585-A Degradants and degreddeterminants for target protein degradation C4医药公司 2020-07-03 — — CN disclosed
WO-2017049462-A1 NOVEL FLT3 KINASE INHIBITOR AND USES THEREOF 合肥中科普瑞昇生物医药科技有限公司 2017-03-30 — — WO disclosed
US-9421205-B2 FAK inhibitors Cancer Therapeutics CRC Pty Ltd. (AU) 2016-08-23 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS ASANA BIOSCIENCES, LLC (US) 2016-08-04 — — US disclosed
US-9266864-B2 VEGFR3 inhibitors CANCER THERAPEUTICS CRC PTY LIMITED (AU) 2016-02-23 — — US disclosed
EP-2025675-A1 Arylsulfonamides with analgetic activity Boehringer Ingelheim International GmbH (DE) 2009-02-18 — — EP disclosed
US-20080293688-A1 AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2008-11-27 — — US disclosed
US-20080293688-A1 AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2008-11-27 — — US disclosed
US-20080293688-A1 AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2008-11-27 — — US disclosed
WO-2008144299-A1 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS WYETH (US) 2008-11-27 — — WO disclosed
WO-2008144299-A1 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS WYETH (US) 2008-11-27 — — WO disclosed
WO-2008022945-A1 ARYL SULFONAMIDES WITH AN ANALGESIC ACTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-28 — — WO disclosed
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases CAPRARO HANS-GEORG 2007-09-13 — — US disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 — — EP disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293688-A1 AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS HTR6, HTR3B, HTR5A MAPT 2500/4885ALDH1A1 771/4885LMNA 4424/4885
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 MAPT 2440/4885ALDH1A1 1704/4885LMNA 3688/4885
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases ABL1, PRKCA, PRKCQ MAPT 1440/4885ALDH1A1 2948/4885LMNA 1093/4885
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION STUB1, MDM2, USP30 MAPT 949/4885ALDH1A1 3735/4885LMNA 2540/4885
US-20160222014-A1 COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS SRC, PTK2, FYN MAPT 3391/4885ALDH1A1 3377/4885LMNA 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.